See What HealthDay Can Do For You
Contact Us

Kombiglyze XR Approved for Adult Type 2 Diabetes

For once-daily blood sugar control

FRIDAY, Nov. 5, 2010 (HealthDay News) -- The combination drug Kombiglyze (saxagliptin, metformin XR) has been approved by the U.S. Food and Drug Administration to help control blood sugar in adults with type 2 diabetes, makers AstraZeneca and Bristol-Myers Squibb said Friday.

Kombiglyze XR combines a DPP-4 inhibitor called saxagliptin (brand name: Onglyza) with a popular biguanide called metformin XR, the companies said in a news release.

The combination drug has a boxed label warning for lactic acidosis, a rare but serious complication caused by accumulation of metformin, the drug makers said.

Approval of the combined active ingredients in Kombiglyze XR was based on clinical studies involving more than 2,000 adults with type 2 diabetes. The most common adverse reactions were diarrhea and nausea/vomiting.

More information

To learn more about type 2 diabetes, visit the American Diabetes Association.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.